Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AssigneeSeattle Genetics, Inc.
InventorsChe-Leung Law, Alan F. Wahl, Nathalie Scholler, Linda A. Pestano
Life of this patent
Estimating the term…
Abstract
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
Claims29
A method for the treatment of a CD70-expressing cancer in a subject, the method comprising:
- administering to the subject, in an amount effective for the treatment thereof, an antibody-drug conjugate comprising an antibody that binds to CD70, wherein:
- (i) the drug is a cytotoxic agent,
- (ii) the antibody is a mouse antibody comprising a heavy chain variable region having the amino acid sequence set forth in residues 20 to 137 of SEQ ID NO:2, and a light chain variable region having the amino acid sequence set forth in residues 21 to 132 of SEQ ID NO:12, or a chimeric or humanized form of the mouse antibody, and
- (iii) the antibody-drug conjugate is internalized into cells, where it exerts a therapeutic effect.
A method for the treatment of a CD70-expressing non-Hodgkin's lymphoma in a human subject, the method comprising:
- administering to the subject, in an amount effective for the treatment thereof an antibody-drug conjugate comprising an antibody that binds to CD70, wherein:
- (i) the drug is a cytotoxic agent, and
- (ii) the antibody-drug conjugate is internalized into cells, where it exerts a therapeutic effect.
Dependencies are inferred from the claim text.